Detailed information for compound 2012998

Basic information

Technical information
  • TDR Targets ID: 2012998
  • Name: 2-[(4-carbamimidoylphenyl)amino]-2-(7-ethyl-3 -methyl-1-benzofuran-5-yl)-N-(1-methylimidazo l-4-yl)sulfonylacetamide
  • MW: 494.566 | Formula: C24H26N6O4S
  • H donors: 3 H acceptors: 4 LogP: 3.03 Rotable bonds: 9
    Rule of 5 violations (Lipinski): 1
  • SMILES: CCc1cc(cc2c1occ2C)C(C(=O)NS(=O)(=O)c1ncn(c1)C)Nc1ccc(cc1)C(=N)N
  • InChi: 1S/C24H26N6O4S/c1-4-15-9-17(10-19-14(2)12-34-22(15)19)21(28-18-7-5-16(6-8-18)23(25)26)24(31)29-35(32,33)20-11-30(3)13-27-20/h5-13,21,28H,4H2,1-3H3,(H3,25,26)(H,29,31)
  • InChiKey: LEMRRMFCXFRTIF-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 2-[(4-carbamimidoylphenyl)amino]-2-(7-ethyl-3-methyl-benzofuran-5-yl)-N-(1-methylimidazol-4-yl)sulfonyl-acetamide
  • 2-[(4-carbamimidoylphenyl)amino]-2-(7-ethyl-3-methyl-5-benzofuranyl)-N-[(1-methyl-4-imidazolyl)sulfonyl]acetamide
  • 2-[(4-amidinophenyl)amino]-2-(7-ethyl-3-methyl-benzofuran-5-yl)-N-(1-methylimidazol-4-yl)sulfonyl-acetamide
  • 2-[(4-carbamimidoylphenyl)amino]-2-(7-ethyl-3-methyl-1-benzofuran-5-yl)-N-(1-methylimidazol-4-yl)sulfonyl-ethanamide

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens suppression of tumorigenicity 14 (colon carcinoma) Starlite/ChEMBL References
Homo sapiens HGF activator Starlite/ChEMBL References
Homo sapiens hepsin Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Echinococcus granulosus Mastin hepsin 417 aa 337 aa 23.4 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Brugia malayi Muscle positioning protein 4 0.003 0.5771 1
Leishmania major hypothetical protein, conserved 0.0018 0.099 0.5
Plasmodium falciparum cysteine repeat modular protein 1 0.0018 0.099 0.5
Echinococcus multilocularis tissue type plasminogen activator 0.0018 0.099 0.5
Onchocerca volvulus 0.0025 0.384 0.5962
Onchocerca volvulus 0.0025 0.384 0.5962
Echinococcus granulosus tissue type plasminogen activator 0.0018 0.099 0.5
Loa Loa (eye worm) DOMON domain-containing protein 0.0025 0.384 0.5962
Schistosoma mansoni hypothetical protein 0.0018 0.099 0.099
Onchocerca volvulus 0.0025 0.384 0.5962
Loa Loa (eye worm) hypothetical protein 0.0025 0.384 0.5962
Loa Loa (eye worm) hypothetical protein 0.003 0.5771 1
Schistosoma mansoni hypothetical protein 0.0025 0.384 0.384
Trypanosoma cruzi hypothetical protein, conserved 0.0018 0.099 0.5
Plasmodium vivax cysteine repeat modular protein 1, putative 0.0018 0.099 0.5
Schistosoma mansoni subfamily S1A unassigned peptidase (S01 family) 0.002 0.1735 0.1735
Brugia malayi SEA domain containing protein 0.0025 0.384 0.5962
Onchocerca volvulus 0.0025 0.384 0.5962
Toxoplasma gondii kringle domain-containing protein 0.0018 0.099 0.5
Onchocerca volvulus 0.003 0.5771 1

Activities

Activity type Activity value Assay description Source Reference
Ki (binding) = 553 nM Inhibition of hepsin (unknown origin) using Boc-QAR-AMC as substrate after 30 mins prior to substrate addition by fluorescence assay ChEMBL. 25882520
Ki (binding) = 7100 nM Inhibition of recombinant N-terminal His-tagged HGFA (unknown origin) expressed in baculovirus-infected Sf9 cells using Boc-QLR-AMC as substrate incubated for 30 mins prior to substrate addition by fluorescence assay ChEMBL. 25882520
Ki (binding) = 7180 nM Inhibition of matripase (unknown origin) using Boc-QAR-AMC as substrate incubated for 30 mins prior to substrate addition by fluorescence assay ChEMBL. 25882520

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.